VX-950: Phase Ib data

In a double-blind, placebo-controlled, European Phase Ib trial in 34 patients, 26 of 28 patients receiving VX-950 achieved >3 log reduction in plasma HCV-RNA within 2 days. After 14 days, patients tak...